logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Pfizer Tops Estimates in Second Quarter, Reiterates Full Year Outlook

By  +Follow July 30, 2013 8:52AM
Share:
Tickers Mentioned:

Pfizer Inc. (PFE) , the biggest drugmaker in the world, on Tuesday reported second-quarter earnings that nipped past analyst predictions as the company fought through declining sales that were hamstringed by the loss of exclusivity on the blockbuster cholesterol fighter Lipitor.

For the quarter, NYC-based Pfizer said it generated $12.97 billion in revenue, compared to $13.97 billion in the second quarter last year.  Net income soared to $14.1 billion, or $1.98 per share, versus $3.25 billion, or 43 cents per share, in last year’s quarter.  In February, Pfizer spun-out its animal health business into a new company called Zoetis, Inc. (ZTS) .  In December 2012, it sold its nutrition business to Nestle SA ($NSRGY) for $11.85 billion, accounting for most of the surge in reported income.  Excluding gains from the sale, restructuring costs and other special items, adjusted profits for the second quarter totaled $4.0 billion, or 56 cents per share, compared to $4.45 billion, or 59 cents per share, in the year prior quarter.

Wall Street was expecting EPS of 55 cents on revenue of $13.01 billion.

Sales of Lipitor sank 55 percent from $1.22 billion in the second quarter of 2012 to $545 million in the latest quarter.  Sales of pneumococcal vaccine Prevnar slipped 3 percent to $969 million due to changes in government purchasing patterns.  Counterbalancing those losses, sales of Pfizer’s biggest drug Lyrica, which is indicated for fibromyalgia, diabetic nerve pain and more, improved by 10 percent to $1.13 billion.

Revenue for Pfizer’s leading business units – primary care, specialty care, emerging markets and established products – all declined compared to the year prior quarter.  Ian Read, chairman and chief executive at Pfizer, said in today’s statement that he expects emerging market business growth to accelerate in the second of the year, led by China.

“From a total company view, we are tracking to our expectations for the full year and continue to capitalize on the investments we are making to better position Pfizer for long-term success,” added Read.

The company backed its 2013 forecast of adjusted earnings in the range of $2.10 to $2.20 per share.

Sales of anti-cancer drugs rose 24 percent to $399 million, boosted in part by a 191-percent climb in sales of Xalkori to $67 million and $17 million in sales from new drug Inlyta.

Operating margin improved significantly from 29.9 percent to 41.3 percent.

Marking “the next step in Pfizer’s journey to further revitalize [its] innovative core,” Pfizer said on Monday that it intends to split its company into three new units.  One unit will focus on drugs that are patent-protected beyond 2015.  The second will include vaccines, oncology and consumer healthcare products.  The third will include drugs that have lost – or will soon lose – patent exclusivity, generics and future product collaborations.  The changes are slated to start happening in January.

Two new drugs, blood thinner Eliquis and rheumatoid arthritis drug Xeljanz, are thought by many to have the capabilities to grow into blockbusters, although Zeljanz is facing some hurdles in Europe with negative opinions being offered by a European Medicines Agency committee.  Zeljanz generated $33 million in sales in the second quarter. The FDA is reviewing a supplemental New Drug Application (NDA) for Zeljanz with a decision expected by February.  Topline results are expected from two ongoing phase 3 trials evaluating Zeljanz in the second quarter next year.  The FDA is also reviewing a supplemental NDA for Eliquis, with a decision expected by March 15, 2014. 

During the second quarter, Pfizer repurchased $3.3 billion worth of its common stock, bringing its first-half total to $8.7 billion.

Shares of PFE have risen 20 percent so far in 2013 through Monday’s close at $29.54.  

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for PFE
Langan Stocks
20 Dec 14 09:29:11
$GOOG Investor Opinions Updated Saturday, December 20, 2014 12:03:25 PM $ABBV $DBA $PFE $SMN http://t.co/EI5PGkNBNH
Caesar
20 Dec 14 08:07:16
@cells_nnm @portefeuillefun That's essentially Pfizer $PFE chose Cellectis $ALCLS.PA Allogeneic CART is cheaper to produce
PolgarStocks
20 Dec 14 07:28:13
$SLTD Recent News Updated Saturday, December 20, 2014 10:07:23 AM $CAT $SAVE $PFE $AA http://t.co/flLL9tLZN8
Rosner Stocks
20 Dec 14 07:28:13
$GDXJ Company Info Updated Saturday, December 20, 2014 09:59:24 AM $XOP $PFE $URI $SH http://t.co/zrOxR1sZ8w
FinSentS SP500
20 Dec 14 07:18:48
$PFE:US AstraZeneca CEO says new Pfizer bid unlikely: Swedish daily DI #PFIZER INC http://t.co/byEPAJODhq #SP500
ProTradersNews
20 Dec 14 06:38:02
$PFE: Pfizer Inc. (NYSE:PEE) (PFE) Results from Phase III of Nerve-Pain ... http://t.co/myOZFUW8BT http://t.co/9wS6QIwEM0
StockNewsWires
20 Dec 14 06:03:03
$LLY $PFE $JNJ: Beta-amyloid: the emperor really does have no clothes http://t.co/fUNCJ3ahYr http://t.co/6cCSurWSpq
Greg Levett
20 Dec 14 05:42:24
AstraZeneca CEO tells Dagens Industri "I consider it unlikely that Pfizer will return with a bid." http://t.co/cQwIuCQIyi $AZN $PFE
Rosner Stocks
20 Dec 14 05:27:18
$BABA Recent News Updated Saturday, December 20, 2014 07:59:25 AM $WLL $OIH $PFE $SMN http://t.co/tbIYFZwwW8
Rosner Stocks
20 Dec 14 04:25:48
$KO Percent Change Updated Saturday, December 20, 2014 06:59:25 AM $BEAV $DGLY $PFE $BP http://t.co/soKHM8ETR9
Rosner Stocks
20 Dec 14 03:24:40
$VHC Stock Price Updated Saturday, December 20, 2014 05:59:25 AM $ONVO $XOM $GS $PFE http://t.co/EWvUSRkEH3
12Stocks.com
20 Dec 14 03:01:15
Weekly Dow #Stocks Trend $DD $MMM $UNH $PG $UTX $TRV $HD $PFE $JPM $CSCO $GS $AXP $V $XOM $DIS $WMT $MSFT $CVX @ http://t.co/TvzJfdisOX
IH News Desk
20 Dec 14 02:39:18
$HIMX Filings Updated Saturday, December 20, 2014 05:11:23 AM $BLTA $PFE $HD $SWKS http://t.co/U9knTZyZSR
IH News Desk
20 Dec 14 01:38:10
$X Stock Message Board Updated Saturday, December 20, 2014 04:11:24 AM $GILD $TVIX $DIA $PFE http://t.co/LCS44axVex
Kai Jäckl
20 Dec 14 01:34:24
@MarcelitoMaura: The next to NASH? ONE HINT -- Its not $ICPT http://t.co/pbNKehTMM2 $ARNA $PFE Belviq will be the next NASH blockbuster $AR
Leonie Machado
20 Dec 14 01:02:32
Would you like great research on stocks $PFE $ICE $CMCSA $ABX Give it a try http://t.co/sjSDzMH5Q9
Dangelo Cadwell
20 Dec 14 00:45:50
Sick and Tired of losing money on $PFE $GGG $INGR $SLW #financial http://t.co/sE5hRgUPqH
Greg Levett
19 Dec 14 23:41:22
Soriot says AstraZeneca will have to be "lucky" to hit $45bn sales forecast. Danger of $PFE returning "always there." http://t.co/VlDlYqiW44
IH News Desk
19 Dec 14 23:36:36
$UUP Percent Change Updated Saturday, December 20, 2014 02:11:26 AM $GGAL $ATHN $CAT $PFE http://t.co/tgYZNZpDp7
Langan Stocks
19 Dec 14 23:21:32
$SVXY Short Sales Updated Saturday, December 20, 2014 02:03:25 AM $IMSC $USO $PFE $BBBY http://t.co/BGGvZEuCVo
Langan Stocks
19 Dec 14 22:21:41
$GGAL Short Sales Updated Saturday, December 20, 2014 01:03:26 AM $PFE $GLD $PFE $SGLB http://t.co/9En0UtLyii
PolgarStocks
19 Dec 14 22:21:05
$DGLY Financials Updated Saturday, December 20, 2014 01:07:26 AM $PFE $ETFC $DXJ $QCOM http://t.co/BkP5pwp7HN
Scott Spencer
19 Dec 14 21:21:40
$GILD +3% $108.67 $BIIB $BMY Three pharma giants growing significantly faster than $PFE... http://t.co/KS9pCUlU1f
Rosner Stocks
19 Dec 14 21:17:07
$PFE Recent News Updated Friday, December 19, 2014 11:59:25 PM $PPLT $ARTX $PG $EWA http://t.co/VFlZOmMDNW
Rolly Custodio
19 Dec 14 20:27:38
@MarcelitoMaura: The next to NASH? ONE HINT -- Its not $ICPT http://t.co/qaNdkAnxqa $ARNA $PFE Belviq will be the next NASH blockbuster $ARN
Alpha Maven
19 Dec 14 19:58:15
RT @SeekingAlpha: 7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends http://t.co/yotYzPZ4cj $ABT $BA $GE $LL…
Chris Reynolds
19 Dec 14 19:52:37
RT @SeekingAlpha: 7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends http://t.co/yotYzPZ4cj $ABT $BA $GE $LL…
Joe Attrux
19 Dec 14 19:47:14
RT @SeekingAlpha: 7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends http://t.co/yotYzPZ4cj $ABT $BA $GE $LL…
Alysia Sarkisian
19 Dec 14 19:15:35
RT @SeekingAlpha: 7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends http://t.co/yotYzPZ4cj $ABT $BA $GE $LL…
John Michael
19 Dec 14 19:14:14
RT @SeekingAlpha: 7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends http://t.co/yotYzPZ4cj $ABT $BA $GE $LL…
awolam
19 Dec 14 19:13:46
RT @SeekingAlpha: 7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends http://t.co/yotYzPZ4cj $ABT $BA $GE $LL…
Quantpost Healthcare
19 Dec 14 19:11:22
$PFE News: "7 Stocks Providing Their Shareholders A Growing Income With Higher…" http://t.co/72eNHf4vmR Board view: https://t.co/X4YySKkXQN
Seeking Alpha
19 Dec 14 19:11:20
7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends http://t.co/yotYzPZ4cj $ABT $BA $GE $LLY $MMM $O $PFE
Fernando Bala
19 Dec 14 18:34:25
@MarcelitoMaura: The next to NASH? ONE HINT -- Its not $ICPT http://t.co/PkKmHvh9ML $ARNA $PFE Belviq will be the next NASH blockbuster $ARN
PolgarStocks
19 Dec 14 17:16:10
$DIA Short Sales Updated Friday, December 19, 2014 8:07:23 PM $AMRN $PFE $KO $EVRM http://t.co/JqwT6Ni9og
StockNewsWires
19 Dec 14 16:53:05
$PFE: Traders Sell Shares of Pfizer on Strength (PFE) http://t.co/ig5HJ5ac3F http://t.co/lwPUJYa7EY
Rosner Stocks
19 Dec 14 16:13:11
$BABA Stock Price Updated Friday, December 19, 2014 6:59:24 PM $CUBA $UUP $TVIX $PFE http://t.co/iMlPURXh64
Rosner Stocks
19 Dec 14 16:13:06
$RIG Percent Change Updated Friday, December 19, 2014 6:59:24 PM $XHB $GE $XLI $PFE http://t.co/ZNo2AAUjsX
Savanna Teel
19 Dec 14 16:02:25
Awesome #Stock #Research on $PFE $HCN $CPT $IR Visit http://t.co/m2gV6t1hNe
12Stocks.com
19 Dec 14 16:01:14
Dow #Stocks Trend $DD $UNH $MMM $PG $HD $TRV $UTX $JPM $PFE $CSCO $GS $AXP $V $XOM $DIS $WMT $MSFT $CVX $NKE @ http://t.co/TvzJfdisOX
FinSentS SP500
19 Dec 14 15:40:29
$PFE:US Pfizer's Duchenne Muscular Dystrophy Drug in Phase II #PFIZER INC http://t.co/bxrHkeqrPd #SP500
Zandra Whitlock
19 Dec 14 15:25:40
This weeks Stocks you should Watch $GXP $PFE $CNK $CBM #singedinvestor http://t.co/TDVVfVwNco
Charlie
19 Dec 14 15:24:52
$ARIA CEO Harvey Berger buys $160,000 in $ARIA stock! #cnbc #msnbc $pfe $ctic #POTUS $gsk $bac $ge #money #investing #gaza #Israel
Langan Stocks
19 Dec 14 15:15:12
$MU Last Price Updated Friday, December 19, 2014 6:03:32 PM $PFE $UNH $F $DUST http://t.co/vxlfxQv4bV
Nedra Barkley
19 Dec 14 15:10:15
Should you buy, sell or hold $NAV $AZO $PFE $IR I suggest http://t.co/OD2JHT65tP
ProVesting
19 Dec 14 14:29:03
$GILD $PFE: United Therapeutics Lung Drug Keeps Going And Going http://t.co/sf6udqgpXN http://t.co/QPUwEgUFRU
Shawn Hager
19 Dec 14 14:20:58
Did you lose money on $PDCO $PFE $TER $AAPL Must have http://t.co/n2LaILzfYn
PolgarStocks
19 Dec 14 14:13:40
$AAPL Last Price Updated Friday, December 19, 2014 5:07:38 PM $PFE $FITX $SGLB $AMD http://t.co/AmIfnCAJiO
Rosner Stocks
19 Dec 14 14:12:08
$XLP Opinions Updated Friday, December 19, 2014 4:59:24 PM $UNG $EEM $SWKS $PFE http://t.co/PfpYfy8yTA
Bidness Etc
19 Dec 14 13:49:48
#Pfizer Reports Positive Phase III Results For Nerve-Pain Drug http://t.co/TMeOQCpXrZ $PFE http://t.co/Gyik3uQzOP
				
				
By  +Follow July 30, 2013 8:52AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.